Myriad Genetics, Inc. (0K3W.L)
USD 14.11
(0.53%)
USD 14.11
(0.53%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | -123.7 Million USD | -154.0% |
| 2021 | -48.7 Million USD | 75.0% |
| 2020 | -194.8 Million USD | -2663.16% |
| 2019 | 7.6 Million USD | 0.0% |
| 2018 | 7.6 Million USD | -93.6% |
| 2017 | 118.7 Million USD | 140.28% |
| 2016 | 49.4 Million USD | -70.38% |
| 2015 | 166.8 Million USD | 24.29% |
| 2014 | 134.2 Million USD | -51.1% |
| 2013 | 274.44 Million USD | 20.37% |
| 2012 | 228 Million USD | 26.44% |
| 2011 | 180.31 Million USD | 14.29% |
| 2010 | 157.77 Million USD | 16.81% |
| 2009 | 135.07 Million USD | 6.81% |
| 2008 | 126.46 Million USD | 232.09% |
| 2007 | 38.08 Million USD | 179.79% |
| 2006 | -47.72 Million USD | -4.69% |
| 2005 | -45.58 Million USD | -11.89% |
| 2004 | -40.74 Million USD | 4.43% |
| 2003 | -42.63 Million USD | -55.91% |
| 2002 | -27.34 Million USD | -46.55% |
| 2001 | -18.65 Million USD | -42.05% |
| 2000 | -13.13 Million USD | -13.76% |
| 1999 | -11.54 Million USD | 6.88% |
| 1998 | -12.4 Million USD | 4.62% |
| 1997 | -13 Million USD | -4.0% |
| 1996 | -12.5 Million USD | -40.45% |
| 1995 | -8.9 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q1 | -52.2 Million USD | -13.48% |
| 2023 Q3 | -60.1 Million USD | 47.14% |
| 2023 Q2 | -113.7 Million USD | -117.82% |
| 2022 Q4 | -46 Million USD | -2.22% |
| 2022 Q3 | -45 Million USD | -152.81% |
| 2022 Q2 | -17.8 Million USD | -19.46% |
| 2022 Q1 | -14.9 Million USD | 65.43% |
| 2022 FY | -123.7 Million USD | -154.0% |
| 2021 Q4 | -43.1 Million USD | 46.06% |
| 2021 Q2 | -20.8 Million USD | 55.46% |
| 2021 Q1 | -46.7 Million USD | 3.11% |
| 2021 FY | -48.7 Million USD | 75.0% |
| 2021 Q3 | -79.9 Million USD | -284.13% |
| 2020 Q3 | -39.6 Million USD | 42.02% |
| 2020 FY | -194.8 Million USD | -2663.16% |
| 2020 Q2 | -68.3 Million USD | 48.92% |
| 2020 Q1 | -133.7 Million USD | -1419.32% |
| 2020 Q4 | -48.2 Million USD | -21.72% |
| 2019 Q1 | 5.9 Million USD | -3.28% |
| 2019 Q2 | -5.6 Million USD | -194.92% |
| 2019 Q3 | -20.9 Million USD | -273.21% |
| 2019 Q4 | -8.8 Million USD | 57.89% |
| 2019 FY | 7.6 Million USD | 0.0% |
| 2018 Q2 | 15.9 Million USD | -6.47% |
| 2018 Q4 | 6.1 Million USD | 408.33% |
| 2018 FY | 7.6 Million USD | -93.6% |
| 2018 Q1 | 17 Million USD | 286.36% |
| 2018 Q3 | 1.2 Million USD | -92.45% |
| 2017 Q1 | 12.9 Million USD | -2.27% |
| 2017 Q4 | 4.4 Million USD | -94.97% |
| 2017 FY | 118.7 Million USD | 140.28% |
| 2017 Q3 | 87.4 Million USD | 411.11% |
| 2017 Q2 | 17.1 Million USD | 32.56% |
| 2016 Q4 | 13.2 Million USD | 112.9% |
| 2016 Q2 | 35.7 Million USD | -16.2% |
| 2016 Q1 | 42.6 Million USD | -5.75% |
| 2016 FY | 49.4 Million USD | -70.38% |
| 2016 Q3 | 6.2 Million USD | -82.63% |
| 2015 Q3 | 43.3 Million USD | 19.61% |
| 2015 FY | 166.8 Million USD | 24.29% |
| 2015 Q1 | 35.74 Million USD | -1.66% |
| 2015 Q2 | 36.2 Million USD | 1.29% |
| 2015 Q4 | 45.2 Million USD | 4.39% |
| 2014 Q3 | 25.92 Million USD | -51.32% |
| 2014 Q4 | 36.34 Million USD | 40.21% |
| 2014 FY | 134.2 Million USD | -51.1% |
| 2014 Q1 | 55.28 Million USD | -33.39% |
| 2014 Q2 | 53.25 Million USD | -3.68% |
| 2013 Q2 | 65.91 Million USD | 13.81% |
| 2013 Q1 | 57.91 Million USD | 4.2% |
| 2013 FY | 274.44 Million USD | 20.37% |
| 2013 Q4 | 82.99 Million USD | 0.11% |
| 2013 Q3 | 82.9 Million USD | 25.77% |
| 2012 FY | 228 Million USD | 26.44% |
| 2012 Q1 | 46.09 Million USD | 1.39% |
| 2012 Q4 | 55.58 Million USD | 14.42% |
| 2012 Q3 | 48.58 Million USD | 2.74% |
| 2012 Q2 | 47.28 Million USD | 2.58% |
| 2011 Q2 | 41.77 Million USD | -0.11% |
| 2011 Q4 | 45.46 Million USD | 9.63% |
| 2011 FY | 180.31 Million USD | 14.29% |
| 2011 Q1 | 41.82 Million USD | 8.39% |
| 2011 Q3 | 41.47 Million USD | -0.73% |
| 2010 FY | 157.77 Million USD | 16.81% |
| 2010 Q3 | 35.59 Million USD | -5.38% |
| 2010 Q2 | 37.61 Million USD | 13.21% |
| 2010 Q1 | 33.22 Million USD | -3.76% |
| 2010 Q4 | 38.58 Million USD | 8.42% |
| 2009 Q1 | 22.31 Million USD | 25.58% |
| 2009 Q4 | 34.52 Million USD | 16.19% |
| 2009 Q3 | 29.71 Million USD | -59.34% |
| 2009 Q2 | 73.07 Million USD | 227.52% |
| 2009 FY | 135.07 Million USD | 6.81% |
| 2008 Q1 | -7.81 Million USD | 10.53% |
| 2008 FY | 126.46 Million USD | 232.09% |
| 2008 Q4 | 17.76 Million USD | 33.46% |
| 2008 Q3 | 13.31 Million USD | -79.9% |
| 2008 Q2 | 66.21 Million USD | 947.16% |
| 2007 Q3 | -11.58 Million USD | 5.58% |
| 2007 Q2 | -12.26 Million USD | -34.91% |
| 2007 Q1 | -9.09 Million USD | -179.97% |
| 2007 FY | 38.08 Million USD | 179.79% |
| 2007 Q4 | -8.73 Million USD | 24.57% |
| 2006 Q2 | -13.98 Million USD | -16.96% |
| 2006 Q1 | -11.95 Million USD | -24.52% |
| 2006 FY | -47.72 Million USD | -4.69% |
| 2006 Q4 | 11.36 Million USD | 175.79% |
| 2006 Q3 | -15 Million USD | -7.29% |
| 2005 Q4 | -9.6 Million USD | 4.51% |
| 2005 FY | -45.58 Million USD | -11.89% |
| 2005 Q2 | -8.74 Million USD | 18.38% |
| 2005 Q1 | -10.71 Million USD | -0.32% |
| 2005 Q3 | -10.05 Million USD | -15.01% |
| 2004 Q2 | -10.92 Million USD | 2.17% |
| 2004 Q1 | -11.16 Million USD | -7.54% |
| 2004 Q3 | -10.61 Million USD | 2.79% |
| 2004 Q4 | -10.67 Million USD | -0.56% |
| 2004 FY | -40.74 Million USD | 4.43% |
| 2003 Q1 | -6.11 Million USD | 18.4% |
| 2003 Q2 | -7.67 Million USD | -25.58% |
| 2003 Q3 | -10.16 Million USD | -32.5% |
| 2003 FY | -42.63 Million USD | -55.91% |
| 2003 Q4 | -10.38 Million USD | -2.09% |
| 2002 Q4 | -7.48 Million USD | -23.34% |
| 2002 FY | -27.34 Million USD | -46.55% |
| 2002 Q3 | -6.07 Million USD | 18.69% |
| 2002 Q2 | -7.46 Million USD | -68.11% |
| 2002 Q1 | -4.44 Million USD | -17.43% |
| 2001 Q4 | -3.78 Million USD | -27.48% |
| 2001 FY | -18.65 Million USD | -42.05% |
| 2001 Q1 | -3.25 Million USD | -1.67% |
| 2001 Q2 | -3.45 Million USD | -6.03% |
| 2001 Q3 | -2.96 Million USD | 14.1% |
| 2000 FY | -13.13 Million USD | -13.76% |
| 2000 Q4 | -3.2 Million USD | 0.49% |
| 2000 Q1 | -3.02 Million USD | -31.43% |
| 2000 Q2 | -3.5 Million USD | -15.95% |
| 2000 Q3 | -3.22 Million USD | 8.13% |
| 1999 Q2 | -3 Million USD | -15.38% |
| 1999 Q1 | -2.6 Million USD | 27.78% |
| 1999 FY | -11.54 Million USD | 6.88% |
| 1999 Q4 | -2.3 Million USD | 14.81% |
| 1999 Q3 | -2.7 Million USD | 10.0% |
| 1998 Q4 | -3.6 Million USD | -5.88% |
| 1998 FY | -12.4 Million USD | 4.62% |
| 1998 Q1 | -3.5 Million USD | -12.9% |
| 1998 Q2 | -3.8 Million USD | -8.57% |
| 1998 Q3 | -3.4 Million USD | 10.53% |
| 1997 Q1 | -4 Million USD | 6.98% |
| 1997 Q2 | -500 Thousand USD | 87.5% |
| 1997 Q3 | -2.7 Million USD | -440.0% |
| 1997 FY | -13 Million USD | -4.0% |
| 1997 Q4 | -3.1 Million USD | -14.81% |
| 1996 Q3 | -3.7 Million USD | -27.59% |
| 1996 FY | -12.5 Million USD | -40.45% |
| 1996 Q1 | -2.7 Million USD | -42.11% |
| 1996 Q4 | -4.3 Million USD | -16.22% |
| 1996 Q2 | -2.9 Million USD | -7.41% |
| 1995 Q4 | -1.9 Million USD | -290.0% |
| 1995 FY | -8.9 Million USD | 0.0% |
| 1995 Q3 | 1 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | 26.883% |
| Dynavax Technologies Corporation | -37.02 Million USD | -234.072% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -2247.694% |
| Perrigo Company plc | 151.9 Million USD | 181.435% |
| Illumina, Inc. | -1.06 Billion USD | 88.428% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 101.803% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 73.141% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 99.121% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 106.257% |
| Heron Therapeutics, Inc. | -110.61 Million USD | -11.829% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 103.057% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -176.938% |
| Waters Corporation | 817.67 Million USD | 115.128% |
| Biogen Inc. | 1.29 Billion USD | 109.539% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 54.855% |
| Evolus, Inc. | -49.23 Million USD | -151.254% |
| Adicet Bio, Inc. | -152.03 Million USD | 18.639% |
| Cara Therapeutics, Inc. | -121.49 Million USD | -1.815% |
| bluebird bio, Inc. | -244.26 Million USD | 49.358% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 20.482% |
| FibroGen, Inc. | -281.81 Million USD | 56.106% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 109.163% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -174.417% |
| Homology Medicines, Inc. | -48.25 Million USD | -156.346% |
| Geron Corporation | -193.94 Million USD | 36.219% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 56.162% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -68.313% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -22.685% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 75.994% |
| Zoetis Inc. | 3.06 Billion USD | 104.031% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -156.639% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 111.377% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 163.618% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 102.872% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -215.94% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 65.03% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 55.182% |
| Verastem, Inc. | -92.08 Million USD | -34.334% |
| Nektar Therapeutics | -137.42 Million USD | 9.987% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 46.641% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -27.058% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 53.813% |
| OPKO Health, Inc. | -157.02 Million USD | 21.221% |
| Exelixis, Inc. | 170.88 Million USD | 172.388% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 149.303% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 215.304% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -121.86% |
| uniQure N.V. | -282.87 Million USD | 56.27% |
| Imunon, Inc. | -21.03 Million USD | -488.195% |
| Blueprint Medicines Corporation | -486.27 Million USD | 74.562% |
| Insmed Incorporated | -709.62 Million USD | 82.568% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 136.644% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 68.403% |
| TG Therapeutics, Inc. | 20.63 Million USD | 699.525% |
| Incyte Corporation | 620.52 Million USD | 119.935% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 82.971% |